US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
DE602007009932D1
(en)
|
2006-02-16 |
2010-12-02 |
Schering Corp |
PYRROLIDIN DERIVATIVES AS ERK HEMMER
|
SI2526934T1
(en)
|
2006-09-22 |
2016-04-29 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
EP2561875A3
(en)
*
|
2007-03-28 |
2013-06-12 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US8716483B2
(en)
|
2008-02-21 |
2014-05-06 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
AU2009270856B2
(en)
|
2008-07-16 |
2013-07-25 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
|
EP2424368B1
(en)
|
2009-04-29 |
2014-12-31 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
US8846673B2
(en)
|
2009-08-11 |
2014-09-30 |
Bristol-Myers Squibb Company |
Azaindazoles as kinase inhibitors and use thereof
|
US7718662B1
(en)
*
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
TWI535716B
(en)
*
|
2010-05-31 |
2016-06-01 |
Ono Pharmaceutical Co |
Purine ketone derivatives
|
MX342405B
(en)
*
|
2010-06-03 |
2016-09-28 |
Pharmacyclics Inc |
The use of inhibitors of bruton's tyrosine kinase (btk).
|
AU2015275321B2
(en)
*
|
2010-06-03 |
2018-03-15 |
Pharmacyclics Llc |
The use of inhibitors of Bruton's tyrosine kinase (Btk)
|
US8962831B2
(en)
|
2011-05-17 |
2015-02-24 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
US9073947B2
(en)
*
|
2011-06-10 |
2015-07-07 |
Merck Patent Gmbh |
Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
|
WO2013003629A2
(en)
*
|
2011-06-28 |
2013-01-03 |
Pharmacyclics, Inc. |
Methods and compositions for inhibition of bone resorption
|
JP6145451B2
(en)
|
2011-07-08 |
2017-06-14 |
ノバルティス アーゲー |
Novel pyrrolopyrimidine derivatives
|
BR112014000653A2
(en)
*
|
2011-07-13 |
2017-02-14 |
Pharmacyclics Inc |
bruton tyrosine kinase inhibitors
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
JP2014522860A
(en)
*
|
2011-07-19 |
2014-09-08 |
メルク・シャープ・アンド・ドーム・ベー・フェー |
4-Imidazopyridazin-1-yl-benzamide and 4-Imidazotriazin-1-yl-benzamide as BTK inhibitors
|
DK2734522T3
(en)
|
2011-07-19 |
2019-02-18 |
Merck Sharp & Dohme |
4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
|
PL3409278T3
(en)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
EP2773632B1
(en)
*
|
2011-11-03 |
2017-04-12 |
F. Hoffmann-La Roche AG |
8-fluorophthalazin-1(2h)-one compounds as inhibitors of btk activity
|
KR20180034705A
(en)
|
2011-11-29 |
2018-04-04 |
오노 야꾸힝 고교 가부시키가이샤 |
Purinone derivative hydrochloride
|
KR20130076046A
(en)
*
|
2011-12-28 |
2013-07-08 |
한미약품 주식회사 |
Novel imidazopyridine derivatives as a tyrosine kinase inhibitor
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
MX351513B
(en)
*
|
2012-01-19 |
2017-10-17 |
Taiho Pharmaceutical Co Ltd |
3,5-disubstituted alkynylbenzene compound and salt thereof.
|
US8501724B1
(en)
*
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
WO2013118817A1
(en)
*
|
2012-02-07 |
2013-08-15 |
大鵬薬品工業株式会社 |
Quinolyl pyrrolopyrimidine compound or salt thereof
|
MX351863B
(en)
*
|
2012-02-23 |
2017-10-30 |
Taiho Pharmaceutical Co Ltd |
Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof.
|
IN2014MN01897A
(en)
*
|
2012-03-09 |
2015-07-10 |
Carna Biosciences Inc |
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
WO2013177668A1
(en)
*
|
2012-05-31 |
2013-12-05 |
Pharmascience, Inc. |
Protein kinase inhibitors
|
KR20150015021A
(en)
|
2012-06-04 |
2015-02-09 |
파마시클릭스, 인코포레이티드 |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
CA2782774A1
(en)
*
|
2012-07-06 |
2014-01-06 |
Pharmascience Inc. |
Protein kinase inhibitors
|
AU2013293087B2
(en)
*
|
2012-07-24 |
2017-08-31 |
Pharmacyclics Llc |
Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
|
AU2013299557B2
(en)
*
|
2012-08-10 |
2017-06-22 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
|
EP2890691B1
(en)
*
|
2012-08-31 |
2018-04-25 |
Principia Biopharma Inc. |
Benzimidazole derivatives as itk inhibitors
|
WO2014039899A1
(en)
|
2012-09-10 |
2014-03-13 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
PE20151495A1
(en)
|
2012-11-15 |
2015-10-23 |
Pharmacyclics Inc |
PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
|
CN103848810A
(en)
|
2012-11-30 |
2014-06-11 |
北京赛林泰医药技术有限公司 |
Bruton's tyrosine kinases inhibitor
|
US9481682B2
(en)
|
2013-01-23 |
2016-11-01 |
Merck Sharp & Dohme Corp. |
Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
|
US9845329B2
(en)
|
2013-02-22 |
2017-12-19 |
Taiho Pharmaceutical Co., Ltd. |
Method for producing a substituted 6,7,8,9-tetrahydropyrimido[5,4-b]indolizine, substituted 7,8,9,10-tetrahydro-6H-pyrimido[5′,4′:4,5]pyrrolo[1,2-a]azepine and substituted 6,7,8,9,10,11-hexahydropyrimido[5′,4′:4,5]pyrrolo[1,2-a]azocine
|
JO3377B1
(en)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
Pyridinyl and fused pyridinyl triazolone derivatives
|
JP6403751B2
(en)
|
2013-03-14 |
2018-10-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
5-thiazole carboxamine derivatives and their use as BTK inhibitors
|
US8940893B2
(en)
|
2013-03-15 |
2015-01-27 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as BTK inhibitors
|
HRP20220628T1
(en)
*
|
2013-03-15 |
2022-06-24 |
Janssen Pharmaceutica, N.V. |
Processes and intermediates for preparing a medicament
|
JP6118453B2
(en)
*
|
2013-04-02 |
2017-04-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Inhibitor of breton tyrosine kinase
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
EP2999702A4
(en)
*
|
2013-05-21 |
2017-01-11 |
Jiangsu Medolution Ltd. |
Substituted pyrazolopyrimidines as kinases inhibitors
|
US9637487B2
(en)
|
2013-07-02 |
2017-05-02 |
Pharmacyclics Llc |
Purinone compounds as kinase inhibitors
|
JP6084291B2
(en)
|
2013-07-18 |
2017-02-22 |
大鵬薬品工業株式会社 |
Antitumor agent for intermittent administration of FGFR inhibitor
|
JP6084292B2
(en)
*
|
2013-07-18 |
2017-02-22 |
大鵬薬品工業株式会社 |
FGFR inhibitor resistant cancer therapeutics
|
EP3027192A4
(en)
|
2013-08-02 |
2017-03-22 |
Pharmacyclics, LLC |
Methods for the treatment of solid tumors
|
CN105452257B
(en)
*
|
2013-08-12 |
2017-09-05 |
大鹏药品工业株式会社 |
Novel fused pyrimidine compound or its salt
|
ES2709509T3
(en)
|
2013-08-12 |
2019-04-16 |
Pharmacyclics Llc |
Procedures for the treatment of cancer amplified by HER2
|
MA38961A1
(en)
|
2013-09-30 |
2018-05-31 |
Pharmacyclics Llc |
3-phenyl-1h-pyrazolo [3,4-d] pyrimidin-4-ylamine compounds substituted for the crude tyrosine kinase inhibitors used to treat, for example, autoimmune, respiratory and inflammatory diseases, cancer, mastocytosis and osteoporosis
|
JP6615752B2
(en)
|
2013-09-30 |
2019-12-04 |
グアンジョウ・イノケア・ファーマ・テク・カンパニー・リミテッド |
Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune diseases
|
EP4115886A1
(en)
|
2013-10-25 |
2023-01-11 |
Pharmacyclics LLC |
Methods of treating and preventing graft versus host disease
|
CA2833867A1
(en)
*
|
2013-11-21 |
2015-05-21 |
Pharmascience Inc. |
Protein kinase inhibitors
|
US10328080B2
(en)
|
2013-12-05 |
2019-06-25 |
Acerta Pharma, B.V. |
Therapeutic combination of PI3K inhibitor and a BTK inhibitor
|
WO2015095102A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
EP3082809B1
(en)
*
|
2013-12-20 |
2021-01-20 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
JP6486954B2
(en)
|
2014-01-29 |
2019-03-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Pyrazole compounds as BTK inhibitors
|
CN105916859A
(en)
*
|
2014-02-03 |
2016-08-31 |
卡迪拉保健有限公司 |
Heterocyclic compounds
|
BR112016018948B1
(en)
|
2014-02-21 |
2023-01-17 |
Principia Biopharma Inc |
USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, SULFONIC ACID OR CARBOXYLIC ACID SALT OF COMPOUND, AMORPHOUS FORM OF PHARMACEUTICALLY ACCEPTABLE SALT OF COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
|
WO2015143400A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics, Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
WO2015146159A1
(en)
|
2014-03-25 |
2015-10-01 |
Ono Pharmaceutical Co., Ltd. |
Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
|
WO2015181633A2
(en)
|
2014-04-11 |
2015-12-03 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
CN105017256A
(en)
|
2014-04-29 |
2015-11-04 |
浙江导明医药科技有限公司 |
Polyfluorinated compound Bruton tyrosine kinase inhibitor
|
WO2015172713A1
(en)
*
|
2014-05-13 |
2015-11-19 |
广东东阳光药业有限公司 |
Intermediate preparation method
|
CN104086551B
(en)
*
|
2014-06-06 |
2016-09-21 |
人福医药集团股份公司 |
Compound and its production and use
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
TW201613644A
(en)
|
2014-06-17 |
2016-04-16 |
Acerta Pharma Bv |
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
|
KR102073797B1
(en)
*
|
2014-07-07 |
2020-02-05 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
Aminopyridazinone compounds as protein kinase inhibitors
|
CA2959602A1
(en)
|
2014-08-01 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
WO2016022942A1
(en)
|
2014-08-07 |
2016-02-11 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
CN105461720B
(en)
*
|
2014-08-08 |
2019-08-06 |
南京圣和药业股份有限公司 |
Morpholine class tyrosine kinase inhibitor
|
HRP20211813T1
(en)
|
2014-08-11 |
2022-03-04 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
|
CA2965559A1
(en)
*
|
2014-10-30 |
2016-05-06 |
Sandoz Ag |
Active acrylamides
|
CN104407067B
(en)
*
|
2014-11-17 |
2016-01-20 |
广东东阳光药业有限公司 |
The detection method of Buddhist nun and isomeride thereof is replaced according to Shandong
|
CN104447761A
(en)
*
|
2014-11-27 |
2015-03-25 |
广东东阳光药业有限公司 |
Method for preparing pyrazole derivative
|
MA41197B1
(en)
|
2014-12-18 |
2021-01-29 |
Principia Biopharma Inc |
Treatment of pemphigus
|
MA41350A
(en)
*
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
SUMMARY OF A BRUTON TYROSINE KINASE INHIBITOR
|
CN105837576B
(en)
|
2015-01-14 |
2019-03-26 |
湖北生物医药产业技术研究院有限公司 |
BTK inhibitor
|
CN104557945B
(en)
*
|
2015-01-27 |
2017-08-04 |
安润医药科技(苏州)有限公司 |
Buddhist nun's synthetic method is replaced according to Shandong
|
US10214532B2
(en)
*
|
2015-02-12 |
2019-02-26 |
Shanghai Dude Medical Science and Technology Co., Ltd. |
Process for preparing ibrutinib
|
RU2017133990A
(en)
|
2015-03-03 |
2019-04-05 |
Фармасайкликс Элэлси |
PHARMACEUTICAL MEDICINAL FORMS OF BRUTON TYROSINKINASE INHIBITOR
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
CN106146508A
(en)
*
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
The drug combination optimized and treatment cancer and the purposes of autoimmune disease thereof
|
WO2016151438A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of ibrutinib
|
MA41828A
(en)
*
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
CO-CRYSTALS OF A TYROSINE KINASE INHIBITOR FROM BRUTON
|
MA41827A
(en)
*
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
SOLVATED FORMS OF A BRUTON TYROSINE KINASE INHIBITOR
|
CA2980888C
(en)
|
2015-03-31 |
2018-03-06 |
Taiho Pharmaceutical Co., Ltd. |
Crystal of 3,5-disubstituted benzene alkynyl compound
|
CN106146511A
(en)
*
|
2015-04-03 |
2016-11-23 |
安润医药科技(苏州)有限公司 |
Pyrazolopyrimidine derivative, preparation method, pharmaceutical composition and purposes
|
JP6750613B2
(en)
|
2015-04-09 |
2020-09-02 |
小野薬品工業株式会社 |
Process for producing purinone derivative
|
CN106146512B
(en)
*
|
2015-04-09 |
2018-07-17 |
北京睿创康泰医药研究院有限公司 |
The preparation method of Buddhist nun is replaced according to Shandong
|
CN104844573A
(en)
*
|
2015-04-17 |
2015-08-19 |
中国药科大学 |
Miazines BTK inhibitor, preparation method and medical application thereof
|
US20180305350A1
(en)
*
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
ES2895802T3
(en)
|
2015-07-02 |
2022-02-22 |
Acerta Pharma Bv |
Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-inoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N -(pyridin-2-yl)benzamide
|
LV15201B
(en)
|
2015-08-31 |
2017-07-20 |
Latvijas Organiskās Sintēzes Institūts |
The method for the preparation of ibrutinib intermediate
|
WO2017038838A1
(en)
|
2015-09-01 |
2017-03-09 |
大鵬薬品工業株式会社 |
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
|
MA41559A
(en)
*
|
2015-09-08 |
2017-12-26 |
Taiho Pharmaceutical Co Ltd |
CONDENSED PYRIMIDINE COMPOUND OR A SALT THEREOF
|
TW201722957A
(en)
*
|
2015-09-15 |
2017-07-01 |
葛蘭素史克智慧財產(第二)有限公司 |
Chemical compounds
|
EA201890730A1
(en)
|
2015-09-16 |
2018-10-31 |
Локсо Онколоджи, Инк. |
DERIVATIVES OF PYRAZOLOPYRIMIDINE AS BTK INHIBITORS FOR THE TREATMENT OF MALIGNANT NORODUCTURE
|
WO2017106429A2
(en)
|
2015-12-16 |
2017-06-22 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as btk inhibitors
|
SG10202012498TA
(en)
|
2015-12-16 |
2021-01-28 |
Loxo Oncology Inc |
Compounds useful as kinase inhibitors
|
ES2875384T3
(en)
*
|
2016-01-05 |
2021-11-10 |
Jiangsu Hengrui Medicine Co |
Crystal form of BTK kinase inhibitor and method of its preparation
|
EP3402789B1
(en)
|
2016-01-13 |
2020-03-18 |
Boehringer Ingelheim International Gmbh |
Isoquinolones as btk inhibitors
|
CN106995446B
(en)
*
|
2016-01-22 |
2021-07-02 |
山东新时代药业有限公司 |
Preparation method of Bruton's tyrosine kinase inhibitor
|
WO2017134588A1
(en)
|
2016-02-04 |
2017-08-10 |
Shilpa Medicare Limited |
Process for the preparation of ibrutinib
|
CN108602834B
(en)
*
|
2016-02-05 |
2021-01-08 |
北京盛诺基医药科技股份有限公司 |
Bruton's tyrosine kinase inhibitor
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
JP7305352B2
(en)
|
2016-03-31 |
2023-07-10 |
武田薬品工業株式会社 |
isoquinolinyltriazolone complex
|
MX2018012456A
(en)
|
2016-04-12 |
2019-03-07 |
Lilly Co Eli |
Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer.
|
BR112018073673A2
(en)
|
2016-05-20 |
2019-02-26 |
Eli Lilly And Company |
combination therapy with notch and pd-1 or pd-l1 inhibitors
|
CN106083860A
(en)
*
|
2016-06-23 |
2016-11-09 |
艾美科健(中国)生物医药有限公司 |
A kind of synthesis and purifying process replacing Buddhist nun's intermediate according to Shandong
|
MA45547A
(en)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc |
MODIFIED RELEASE FORMULATIONS BASED ON 2- [3- [4-AMINO-3- (2-FLUORO-4-PHENOXY-PHENYL) PYRAZOLO [3,4-D] PYRIMIDINE-1-YL] PIPERIDINE-1-CARBONYL] -4-METHYL-4- [4- (OXETANE-3-YL) PIPERAZINE-1-YL] PENT-2-ENENITRILE
|
JP6715357B2
(en)
*
|
2016-06-30 |
2020-07-01 |
杭州三因泰医薬科技有限公司Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. |
Imidazopyridine amine phenyl derivatives and uses thereof
|
CN107759602B
(en)
*
|
2016-08-17 |
2020-04-21 |
中国科学院上海药物研究所 |
Compound containing conjugated allene structure, pharmaceutical composition and application thereof
|
WO2018033091A1
(en)
*
|
2016-08-17 |
2018-02-22 |
深圳市塔吉瑞生物医药有限公司 |
Fused bicyclic compound for inhibiting activity of tyrosine kinase
|
US10844038B2
(en)
|
2016-09-08 |
2020-11-24 |
Sabila Biosciences Llc |
1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions
|
MA46285A
(en)
|
2016-09-19 |
2019-07-31 |
Mei Pharma Inc |
POLYTHERAPY
|
EP3525796A1
(en)
|
2016-10-12 |
2019-08-21 |
Eli Lilly and Company |
Targeted treatment of mature t-cell lymphoma
|
JP6782855B2
(en)
*
|
2016-11-15 |
2020-11-11 |
杭州和正医薬有限公司 |
Selective Bruton's tyrosine kinase inhibitor and its use
|
JOP20190113A1
(en)
*
|
2016-11-18 |
2019-05-15 |
Biocad Joint Stock Co |
Inhibitors of bruton’s tyrosine kinase
|
CN108101905A
(en)
*
|
2016-11-24 |
2018-06-01 |
中国科学院上海药物研究所 |
Pyrimido [5,4-b] indolizine or pyrimido [5,4-b] pyrrole biopterin compound, preparation method and the usage
|
JP2020511462A
(en)
|
2016-12-03 |
2020-04-16 |
ジュノー セラピューティクス インコーポレイテッド |
Methods and compositions for using therapeutic T cells in combination with kinase inhibitors
|
CN106588937B
(en)
*
|
2017-01-16 |
2018-09-21 |
东莞市真兴贝特医药技术有限公司 |
Imidazopyrazines and its preparation method and application
|
CA3054403A1
(en)
|
2017-02-24 |
2018-08-30 |
Gilead Sciences, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2018156901A1
(en)
|
2017-02-24 |
2018-08-30 |
Gilead Sciences, Inc. |
Inhibitors of bruton's tyrosine kinase
|
AU2018237123B2
(en)
*
|
2017-03-22 |
2022-08-04 |
Xibin Liao |
Bruton's tyrosine kinase inhibitors
|
CN108727230B
(en)
*
|
2017-04-21 |
2021-03-23 |
江苏希迪制药有限公司 |
Ibrutinib intermediate and preparation method thereof
|
CN107043366B
(en)
*
|
2017-04-25 |
2020-05-26 |
中国药科大学 |
4-aminopyrimidine compound, preparation method and medical application thereof
|
CN109111446B
(en)
*
|
2017-06-22 |
2021-11-30 |
上海度德医药科技有限公司 |
Heteroaryl compound with pharmaceutical activity
|
CN107602564B
(en)
*
|
2017-09-20 |
2019-08-30 |
南京亘泰医药技术有限公司 |
Bruton's tyrosine kinase inhibitor
|
TW201922256A
(en)
|
2017-10-27 |
2019-06-16 |
中國大陸商浙江導明醫藥科技有限公司 |
Methods for treating lymphoid malignancies
|
US11100492B2
(en)
|
2018-02-19 |
2021-08-24 |
Peter Garrett |
General purpose re-loadable card aggregation implementation
|
US11028088B2
(en)
*
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
EP3769765B1
(en)
|
2018-03-19 |
2024-04-17 |
Taiho Pharmaceutical Co., Ltd. |
Pharmaceutical composition including sodium alkyl sulfate
|
JP2021524835A
(en)
|
2018-04-05 |
2021-09-16 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
AXL Kinase Inhibitors and Their Use
|
MX2020010556A
(en)
|
2018-04-13 |
2021-03-02 |
Sumitomo Pharma Oncology Inc |
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer.
|
US20210113568A1
(en)
|
2018-04-27 |
2021-04-22 |
Ono Pharmaceutical Co., Ltd. |
PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
|
MX2021000977A
(en)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same.
|
CN111440172B
(en)
*
|
2019-01-17 |
2022-02-11 |
暨南大学 |
Acrylamide compound and application thereof
|
CN111454268B
(en)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
Cyclic molecules as inhibitors of bruton's tyrosine kinase
|
JP2022520361A
(en)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pharmaceuticals containing heterocyclic protein kinase inhibitors
|
WO2020188015A1
(en)
|
2019-03-21 |
2020-09-24 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
WO2021057893A1
(en)
*
|
2019-09-26 |
2021-04-01 |
南京明德新药研发有限公司 |
Pyrazolopyridine compounds as selective btk kinase inhibitors
|
WO2021089791A1
(en)
|
2019-11-08 |
2021-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
TW202140478A
(en)
*
|
2020-03-11 |
2021-11-01 |
英屬開曼群島商百濟神州有限公司 |
Degradation of bruton’s tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
AU2020436612A1
(en)
*
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
US20230382900A1
(en)
*
|
2020-10-30 |
2023-11-30 |
Newave Pharmaceutical Inc. |
Inhibitors of btk
|
CN112574216B
(en)
*
|
2020-12-16 |
2022-03-08 |
天津济坤医药科技有限公司 |
Compound, preparation method thereof and application thereof in preparing anti-cancer drugs
|
CN113004246B
(en)
*
|
2021-02-22 |
2022-02-01 |
广西医科大学 |
1,3, 5-triazine-2-amine-4, 6 substituted derivative or pharmaceutically acceptable salt and application thereof
|
CN113402523B
(en)
*
|
2021-07-13 |
2022-07-12 |
西安交通大学 |
Targeted mast cell MrgX2 small-molecule fluorescent probe and preparation method and application thereof
|
CN114195790B
(en)
*
|
2021-11-18 |
2023-01-06 |
江苏阿尔法药业股份有限公司 |
Synthetic method of ibrutinib
|
CN114276355B
(en)
*
|
2022-01-26 |
2023-04-07 |
江苏阿尔法药业股份有限公司 |
Preparation method of ibrutinib
|
CN114605418B
(en)
*
|
2022-03-15 |
2023-09-05 |
广东医科大学附属医院 |
Ibrutinib acrylamide derivative with anti-tumor activity, and synthetic method and application thereof
|